116 related articles for article (PubMed ID: 30830794)
1. Claims-Based Approach to Predict Cause-Specific Survival in Men With Prostate Cancer.
Riviere P; Tokeshi C; Hou J; Nalawade V; Sarkar R; Paravati AJ; Schiaffino M; Rose B; Xu R; Murphy JD
JCO Clin Cancer Inform; 2019 Mar; 3():1-7. PubMed ID: 30830794
[TBL] [Abstract][Full Text] [Related]
2. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
J Urol; 2019 Sep; 202(3):518-524. PubMed ID: 31009286
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a 5-year mortality prediction model using regularized regression and Medicare data.
Lund JL; Kuo TM; Brookhart MA; Meyer AM; Dalton AF; Kistler CE; Wheeler SB; Lewis CL
Pharmacoepidemiol Drug Saf; 2019 May; 28(5):584-592. PubMed ID: 30891850
[TBL] [Abstract][Full Text] [Related]
4. In search of the perfect comorbidity measure for use with administrative claims data: does it exist?
Baldwin LM; Klabunde CN; Green P; Barlow W; Wright G
Med Care; 2006 Aug; 44(8):745-53. PubMed ID: 16862036
[TBL] [Abstract][Full Text] [Related]
5. Successful external validation of a model to predict other cause mortality in localized prostate cancer.
Kent M; Penson DF; Albertsen PC; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Ehdaie B; Scardino PT; Vickers AJ
BMC Med; 2016 Feb; 14():25. PubMed ID: 26860993
[TBL] [Abstract][Full Text] [Related]
6. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.
Klabunde CN; Legler JM; Warren JL; Baldwin LM; Schrag D
Ann Epidemiol; 2007 Aug; 17(8):584-90. PubMed ID: 17531502
[TBL] [Abstract][Full Text] [Related]
7. Development of a comorbidity index using physician claims data.
Klabunde CN; Potosky AL; Legler JM; Warren JL
J Clin Epidemiol; 2000 Dec; 53(12):1258-67. PubMed ID: 11146273
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Comorbid Medical Conditions in the National Cancer Database and the SEER-Medicare Database.
Lin CC; Virgo KS; Robbins AS; Jemal A; Ward EM
Ann Surg Oncol; 2016 Dec; 23(13):4139-4148. PubMed ID: 27535406
[TBL] [Abstract][Full Text] [Related]
9. The development and validation of a comorbidity index for prostate cancer among Black men.
Fleming ST; Pearce KA; McDavid K; Pavlov D
J Clin Epidemiol; 2003 Nov; 56(11):1064-75. PubMed ID: 14614997
[TBL] [Abstract][Full Text] [Related]
10. Patient Reported vs Claims Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer.
Tan HJ; Zhou X; Spratte BN; McMahon S; Nielsen ME; Lund J; Harris AHS; Smith AB; Basch E
J Urol; 2021 Feb; 205(2):434-440. PubMed ID: 32909877
[TBL] [Abstract][Full Text] [Related]
11. An approach to identifying incident breast cancer cases using Medicare claims data.
Freeman JL; Zhang D; Freeman DH; Goodwin JS
J Clin Epidemiol; 2000 Jun; 53(6):605-14. PubMed ID: 10880779
[TBL] [Abstract][Full Text] [Related]
12. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer.
Sammon JD; Abdollah F; D'Amico A; Gettman M; Haese A; Suardi N; Vickers A; Trinh QD
Eur Urol; 2015 Nov; 68(5):756-65. PubMed ID: 25819724
[TBL] [Abstract][Full Text] [Related]
13. Adapting the Elixhauser comorbidity index for cancer patients.
Mehta HB; Sura SD; Adhikari D; Andersen CR; Williams SB; Senagore AJ; Kuo YF; Goodwin JS
Cancer; 2018 May; 124(9):2018-2025. PubMed ID: 29390174
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of 15-month mortality prediction models: a retrospective observational comparison of machine-learning techniques in a national sample of Medicare recipients.
Berg GD; Gurley VF
BMJ Open; 2019 Jul; 9(7):e022935. PubMed ID: 31315852
[TBL] [Abstract][Full Text] [Related]
15. Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods.
Aly A; Onukwugha E; Woods C; Mullins CD; Kwok Y; Qian Y; Arellano J; Balakumaran A; Hussain A
BMC Med Res Methodol; 2015 Aug; 15():65. PubMed ID: 26286392
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer.
Fleming ST; Rastogi A; Dmitrienko A; Johnson KD
Med Care; 1999 Jun; 37(6):601-14. PubMed ID: 10386572
[TBL] [Abstract][Full Text] [Related]
17. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data.
Wang PS; Walker A; Tsuang M; Orav EJ; Levin R; Avorn J
J Clin Epidemiol; 2000 Jun; 53(6):571-8. PubMed ID: 10880775
[TBL] [Abstract][Full Text] [Related]
18. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Cancer; 2014 Aug; 120(16):2432-9. PubMed ID: 24824511
[TBL] [Abstract][Full Text] [Related]
20. Predicting the 10-year risk of death from other causes in men with localized prostate cancer using patient-reported factors: Development of a tool.
Frendl DM; FitzGerald G; Epstein MM; Allison JJ; Sokoloff MH; Ware JE
PLoS One; 2020; 15(12):e0240039. PubMed ID: 33284845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
